Education
About Us
Working with TipRanks
Follow Us
Labcorp Holdings (LH)
NYSE:LH
Earnings Data
Report Date
Apr 29, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
3.74Last Year’s EPS
3.68Same Quarter Last Year
Strong Buy
Based on 14 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 06, 2025
|% Change Since: -8.41%
|Next Earnings Date:Apr 29, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with strong revenue growth across diagnostics and biopharma segments, successful acquisitions, and promising guidance for 2025. However, there are concerns about margin decline due to acquisitions and higher personnel costs.Company Guidance
During Labcorp's fourth quarter 2024 conference call, the company provided guidance for 2025, projecting enterprise revenue growth between 6.7% and 8%, with improving margins across both diagnostics and biopharma segments. The adjusted EPS is expected to range from $15.60 to $16.40, representing an implied midpoint growth rate of 10%. Labcorp anticipates free cash flow growth in line with earnings, estimating a range of $1.1 billion to $1.25 billion. The company also outlined expectations for diagnostics revenue to grow by 6.5% to 7.7% and biopharma revenue by 3% to 5%, despite a 140-basis-point headwind from foreign currency translation in the biopharma sector. The guidance assumes a continued focus on acquisitions, share repurchases, and dividends, with anticipated capital allocation adjustments throughout the year.Revenue Growth
Revenue for the quarter was $3.3 billion, an increase of 10% compared to the fourth quarter of 2023. Diagnostics and biopharma revenue each grew by approximately 10% in the quarter.
Acquisitions and Strategic Collaborations
Completed acquisitions of select assets and molecular testing locations of Lab Works and select outreach laboratory services for Ballad Health. Announced a strategic collaboration with Inspira Health.
Adjusted EPS Increase
Adjusted EPS of $3.45 was up 5% year-over-year.
Strong Free Cash Flow
Free cash flow from continuing operations was $665 million for the quarter.
Launch of New Diagnostic Tests
Introduced new diagnostics, including a multiple sclerosis monitoring profile and the first companion diagnostic assay to identify gastric cancer patients eligible for targeted treatment.
Expansion in Genetic Testing
Expanded leadership in genetic testing solutions through the acquisition of select assets of Invitae.
Promising 2025 Guidance
Expecting enterprise revenue growth of 6.7% to 8% and improving margins across both diagnostics and biopharma. Anticipated adjusted EPS range of $15.60 to $16.40, representing a midpoint growth rate of 10%.
---
LH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 06, 2025 | $249.28 | $247.03 | -0.90% |
| Oct 24, 2024 | $218.62 | $228.73 | +4.62% |
| Aug 01, 2024 | $213.52 | $231.30 | +8.33% |
| Apr 25, 2024 | $205.33 | $195.86 | -4.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Labcorp Holdings (LH) report earnings?
Labcorp Holdings (LH) is schdueled to report earning on Apr 29, 2025, TBA Not Confirmed.
What is Labcorp Holdings (LH) earnings time?
Labcorp Holdings (LH) earnings time is at Apr 29, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LH EPS forecast?
LH EPS forecast for the fiscal quarter 2025 (Q1) is 3.74.
---